Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, now LeonaBio, reports clinical-stage biopharmaceutical developments centered on novel therapeutics for diseases with high unmet medical needs. Recent company updates reflect the completed name change, the shift to the LONA ticker, and the acquired rights to develop and commercialize lasofoxifene, a selective estrogen receptor modulator for metastatic breast cancer.
The company’s historical Athira updates also cover small-molecule candidates designed to modulate the neurotrophic hepatocyte growth factor system, including ATH-1105 for neurodegenerative diseases such as ALS. Recurring announcements include clinical data presentations, operating and financial results, business updates, capital-structure actions such as the reverse stock split, and governance matters tied to stockholder approvals.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.